Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AR334
- Development stage
- Preclinical
- Lead developer
- Anshi Pharmaceutical
- Modality
- Small Molecules
01
Overview
AR334 is an investigational small molecule therapeutic being developed by Anshi Pharmaceutical for the treatment of obesity. Currently in the preclinical stage of development, AR334 is part of the company's metabolic research portfolio. While the specific pharmacological target and mechanism of action have not been publicly disclosed, the candidate is being evaluated for its potential to manage body weight and address metabolic disorders. It represents one of several early-stage assets in Anshi's pipeline targeting metabolic and endocrine conditions, alongside programs for non-alcoholic steatohepatitis (NASH) and osteoporosis.
Beyond the preview
Go deeper on AR334.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AR334.